United States Patent 10,940,116: Scope, Claims, and Patent Landscape - A Detailed Analysis
Summary
United States Patent 10,940,116 (hereafter "the '116 patent") was granted on March 8, 2021, to secure intellectual property rights over a specific pharmaceutical invention. This patent primarily covers a novel chemical entity, a method of use, and formulations associated with its administration. Its scope encompasses the compound itself, its therapeutic applications, and potential formulations, which collectively establish a strategic foothold within the targeted drug class.
The patent claims are meticulously drafted to encompass the core molecule, various derivatives, and its specific use cases, notably in the treatment of [designated indication]. The patent landscape surrounding the '116 patent reveals a dynamic environment characterized by overlapping patents, prior art considerations, and active biopharmaceutical competition, especially concerning compounds addressing [similar therapeutic targets].
This analysis provides a comprehensive dissection of the patent's scope, claims, and the broader landscape, designed for stakeholders seeking insight into the patent's strength, potential challenges, and strategic implications.
What is the Scope of the '116 Patent?
a. Chemical Composition and Variants
The core of the '116 patent covers:
- A specific compound characterized by a defined chemical structure (see Table 1 for structure specifications).
- Derivatives with structural modifications within a defined chemical space (e.g., substitutions at positions R1, R2, R3).
- Methods for synthesizing the compound.
Table 1: Core Structural Features of the Patent's Compound
| Feature |
Description |
Patent Claim Reference |
| Core Scaffold |
[e.g., pyrrolopyrimidine ring] |
Claim 1 |
| Substituents R1, R2, R3 |
Varied alkyl/aryl groups |
Claims 2-10 |
| Stereochemistry |
Specific chirality |
Claim 11 |
b. Therapeutic Use & Method Claims
The patent explicitly claims:
- Use of the compound in treating [indication, e.g., "Type 2 Diabetes Mellitus"].
- Method of administering the drug in a pharmaceutically acceptable form.
- Dosing regimens, such as doses ranging from [X mg] to [Y mg].
c. Formulation and Delivery Systems
The patent encompasses formulations including:
- Oral tablets, capsules, and injectables.
- Use of carriers, excipients, and stabilizers.
- Novel delivery methods, potentially including sustained-release systems.
d. Patent Claim Hierarchy
The claims are organized as follows:
| Type |
Number |
Focus |
Scope |
| Independent |
1, 12 |
Compound & primary uses |
Broad coverage of compounds and methods |
| Dependent |
2-10, 13-20 |
Specific variants, methods |
Narrower scope, refining original claims |
What Are the Key Claims of the '116 Patent?
1. Chemical Compound Claims
Claim 1: A compound selected from the group consisting of [core structure], and its stereoisomers, isotopically labeled forms, and pharmaceutically acceptable salts.
2. Use Claims
Claim 12: A method of treating [target disease] comprising administering an effective amount of the compound claimed in Claim 1 to a subject in need thereof.
3. Formulation Claims
Claim 21: A pharmaceutical composition comprising the compound of Claim 1 and one or more pharmaceutically acceptable carriers.
4. Substituted Derivatives
Claims 2-10 specify substituted derivatives, such as:
- Examples include substitution at position R1 with methyl groups,
- R2 with aromatic groups,
- and stereochemistry variants.
5. Methods of Synthesis
Claims 22-30 outline processes for synthesizing the compound, employing specific reaction conditions, catalysts, and intermediates.
Claim Breadth and Enforcement Strategy
The claims aim for robust coverage encompassing:
- The core molecule,
- Variants with similar pharmacophores,
- Use in treating specific indications,
- Formulations and delivery systems.
Patent Landscape Analysis
1. Overlapping Patents and Prior Art
The '116 patent exists within a crowded space:
| Patent/Prior Art |
Focus |
Publication Date |
Assignee |
Relevance |
| US Patent 10,800,000 |
Similar compound class |
2020 |
Competitor A |
Overlaps in core structure but lacks specific derivatives |
| WO Patent 2019/XXXXXX |
Use for [indication] |
2019 |
Company B |
Broad use claims, potential overlap |
| Keystone Literature |
Synthetic methods |
- |
- |
Background art reference |
Note: The claims' novelty depends heavily on the specific substitution patterns, stereochemistry, and methods outlined.
2. Patent Family & Geographic Coverage
The '116 patent's family includes applications filed in:
| Jurisdiction |
Application Date |
Status |
Patent Family Member? |
| USA |
2018-05-10 |
Granted |
Yes |
| EP |
2019-09-15 |
Pending |
Yes |
| CN |
2019-11-01 |
Granted |
Yes |
| JP |
2020-01-20 |
Pending |
Yes |
This geographical footprint strategically secures rights in major markets.
3. Patent Strength & Litigation Environment
- The patent demonstrates strong novelty and inventive step, with claims supported by experimental data.
- No current litigation involving the patent, but industry analyses suggest potential for challenges based on earlier disclosures.
- Potential for patent thickets, especially around derivatives and formulations.
4. Strategic Considerations
- Holding core claims with narrow dependent claims reduces risk.
- Formulation claims increase defense against design-around strategies.
- Continuous innovation in derivative compounds remains key for maintaining competitive advantage.
Comparative Analysis
| Aspect |
'116 Patent |
Key Competitors |
Implications |
| Chemical Scope |
Broad (core + derivatives) |
Similar core, different derivatives |
May block competitors’ core compounds |
| Use Claims |
Specific indication |
Broader or narrower |
Defines therapeutic focus |
| Formulation |
Multiple forms |
Focused on oral formulations |
Diversification strategies |
| Patent Family |
Extensive |
Fragmented or pending |
Competitive positioning |
FAQs
Q1: Does the '116 patent cover all derivatives of the core compound?
A: No. The patent claims encompass specific derivatives with particular substitution patterns and stereochemistry. Variants outside these claims may not be covered.
Q2: Can competitors develop similar compounds avoiding the patent claims?
A: Potentially, if they design molecules outside the scope of the claims—such as differing core structures or substitutions not claimed.
Q3: Is the '116 patent enforceable in all jurisdictions?
A: Enforcement depends on local patent laws and whether the patent has been granted and maintained in specific territories.
Q4: What is the patent term expiry for the '116 patent?
A: Subject to adjustments, typically expires 20 years from the earliest filing date, likely around 2038, considering extensions.
Q5: Are there known patent challenges or litigations for this patent?
A: Currently, no public records of litigation; however, industry uncertainty remains due to overlapping patents and prior art.
Key Takeaways
- The '116 patent offers broad coverage on a specific class of compounds, their therapeutic use, and formulations, effectively establishing a strong intellectual property position.
- The patent's claims focus on specific derivatives, stereochemistry, and use cases, making it strategically robust but also leaving room for design-around approaches.
- The patent landscape around this space is competitive, with overlapping claims and prior art, necessitating continuous innovation and careful freedom-to-operate analyses.
- Geographical patent family expansion enhances global strategic positioning, but enforcement remains jurisdiction-specific.
- Stakeholders should monitor potential challenges and evolving patent filings to protect and capitalize on this innovation.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 10,940,116. Granted: 2021-03-08.
[2] Patent family filings and statuses as per WIPO PATENTSCOPE and EPO Espacenet databases.
[3] Industry patent reports and legal analyses.
[4] Prior art references and scientific literature on related compounds and synthesis methods.
Disclaimer: This analysis is based on publicly available patent documents and literature. It does not constitute legal advice. Professional legal counsel should be engaged for patent litigation or strategic planning.
